Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IIa Study of the Efficacy of Single Agent BGJ398 (Infigratinib) in FGFR1-3 Translocated, Mutated, or Amplified Squamous Cell Carcinoma of the Head and Neck

NCT02706691 is registered in ClinicalTrials.gov with University of Chicago as lead sponsor.

NCT NCT02706691
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02706691 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IIa Study of the Efficacy of Single Agent BGJ398 (Infigratinib) in FGFR1-3 Translocated, Mutated, or Amplified Squamous Cell Carcinoma of the Head and Neck
Lead sponsor
University of Chicago
Phase
Phase 2
Overall status
Terminated
Start date
June 1, 2018
Completion date
February 11, 2019
Enrollment
1 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

fgfr gene amplification, fgfr1 gene amplification, fgfr2 gene amplification, fgfr2 gene mutation, fgfr3 gene mutation, head and neck squamous cell carcinoma, human papillomavirus infection, recurrent head and neck carcinoma, recurrent nasopharynx carcinoma, recurrent oropharyngeal squamous cell carcinoma